Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investor Events
  • Pre-market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
February 13, 2012 10:30 AM 4 min read

Is Your iPhone a New Therapist or Antidepressant?

by Louis Bedigian Benzinga Staff Writer
Follow
FlipboardIcon version of the Flipboard logo
Stop popping pills and pick up an iPhone instead.
That's the message being sent by the researchers behind
Mobilyze
, a new iPhone app designed to help users overcome depression. According to
Popular Science
, the app uses a variety of data – such as your location, social activity and physical activity – to determine if a person is behaving normally. If a person is not, the app can do things to help the user overcome his or her negative feelings. For starters, Mobilyze can automatically text the user's family and friends, hoping to spark a motivating conversation. Alternatively, it can text the depressed user and attempt to persuade him/her to reach out to a friend or to get out of the house. Is this a new wave of technological therapy? Not exactly, but it does feel like the beginning of something beautiful. Apple (NASDAQ:
AAPL
on its site
. “His current work targets the treatment and prevention of depression, management of symptoms of chronic illness, and improving adherence to medications.” Dr. Mohr aims to “optimize the usability and effectiveness of BITs” by understanding how people use them, as well as the factors “that influence adherence to BITs interventions through laboratory usability testing.” Those who are interested in participating in the study can
sign up
some
Follow me @LouisBedigian
Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.


Posted In:
TechApp StoreAppleiOSiPhone
AAPL Logo
AAPLApple Inc
$260.40-0.16%
Overview
) has already showed us that the iPhone isn't just for games and Web surfing; it turns out that the popular device can also be used to start a garage band. (Or so the latest Siri commercial loosely claims.) I suppose if you can get Siri to call you “Rock God,” you might as well be able to get a little help with your depression. While medical experts are likely to be against the idea of replacing traditional forms of medication and/or therapy with an iPhone app, it should be noted that Mobilyze is being developed by medical professionals (including David C. Mohr, PhD, who is leading the project) at the Feinberg School of Medicine at Northwestern University in Chicago, IL. “The primary focus of Dr. Mohr's research is to develop and evaluate behavioral intervention technologies (BITs) that harness web-based, mobile and sensor technologies to extend behavioral and psychological care into the patient's environment,” the team explained
now. Only two requirements are provided: you must be at least 19 years old and have access to a computer, broadband Internet, and an e-mail account. (In other words, if you're 19 years or older, you should be good to go.) Thinking ahead, one has to wonder what the world will be like if the iPhone could actually substitute for traditional ways of dealing with depression, if only for more minor cases. This could be a great way to eliminate the hundreds of thousands of unnecessary prescription meds passed around each year. Drug companies wouldn't be too happy about this, as it would surely cut into their bottom line. But it could also reduce the amount of money spent on healthcare each year, which ultimately makes it more affordable for all of us. Mobilyze (and other therapeutic apps) could target health-conscious consumers by reminding them that, unlike traditional prescription meds, these iPhone apps don't come with a full page of side effects. There might not be any side effects at all, actually, which could make the iPhone an ideal alternative. This virtual form of therapy does not have to be limited to iPhones; Android, Windows Phone 7, and other mobile operating systems could also pick it up. But can it really work? At its current stage, Mobilyze will likely be successful in getting
people out of the house, and will probably lead to a few positive conversations with friends or relatives that brighten the mood of those who are depressed. But we don't need an iPhone app for that. For starters, a depressed person could simply go outside. He or she could also pick up the phone and call a friend. No one needs an iPhone to remind them to do that. Where Mobilyze may be most effective is with consumers who rely heavily on technology and are more likely to do something when influenced by their favorite device. For those people, Mobilyze may be just the thing they need to put an end to a depressing day. Long-term, however, as the iPhone and other smartphones become more powerful, as artificial intelligence becomes more intelligent, and as Siri becomes more talkative (and, perhaps, a little more real), we could definitely see a new breed of mood-improving apps.
AAPL Logo
AAPLApple Inc
$260.40-0.16%
Overview
Comments
Loading...